Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) had its price objective boosted by research analysts at Chardan Capital from $4.00 to $5.00 in a research note issued to investors on Friday. The brokerage presently has a “sell” rating on the biopharmaceutical company’s stock. Chardan Capital’s price objective would indicate a potential downside of 40.76% from the stock’s previous close.

A number of other equities research analysts have also weighed in on ACHN. Robert W. Baird reiterated an “outperform” rating and set a $10.00 price objective on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Leerink Swann reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, June 12th. JMP Securities raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research report on Thursday, July 7th. Jefferies Group reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Tuesday, August 9th. Finally, Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $10.70.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 3.44% during mid-day trading on Friday, hitting $8.73. 3,965,640 shares of the stock were exchanged. Achillion Pharmaceuticals has a 52 week low of $5.57 and a 52 week high of $10.95. The company has a 50-day moving average of $8.48 and a 200-day moving average of $8.40. The stock has a market capitalization of $1.19 billion, a PE ratio of 178.16 and a beta of 2.21.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the business posted ($0.25) earnings per share. On average, equities analysts predict that Achillion Pharmaceuticals will post ($0.62) EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. boosted its stake in shares of Achillion Pharmaceuticals by 1.2% in the second quarter. Principal Financial Group Inc. now owns 20,829 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 253 shares during the last quarter. ProShare Advisors LLC boosted its position in Achillion Pharmaceuticals by 0.5% in the second quarter. ProShare Advisors LLC now owns 116,049 shares of the biopharmaceutical company’s stock valued at $905,000 after buying an additional 524 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Achillion Pharmaceuticals by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 32,787 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 937 shares in the last quarter. Creative Planning boosted its position in Achillion Pharmaceuticals by 0.8% in the second quarter. Creative Planning now owns 133,175 shares of the biopharmaceutical company’s stock valued at $1,039,000 after buying an additional 1,000 shares in the last quarter. Finally, BlackRock Group LTD boosted its position in Achillion Pharmaceuticals by 2.2% in the second quarter. BlackRock Group LTD now owns 47,980 shares of the biopharmaceutical company’s stock valued at $374,000 after buying an additional 1,045 shares in the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

5 Day Chart for NASDAQ:ACHN

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.